Triosephosphate Isomerase Level in Relation to Rheumatoid Aerthritis Activity and Structural Damage

Launched by ASSIUT UNIVERSITY · Aug 2, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a substance in the blood called Triosephosphate Isomerase (TPI) to see if its levels are linked to rheumatoid arthritis (RA), a condition that causes joint pain and damage. Researchers want to compare TPI levels in people with RA to those in healthy individuals, and also find out if TPI levels relate to how active the disease is and how much joint damage has occurred, using a special ultrasound scoring system.

Adults diagnosed with rheumatoid arthritis based on standard guidelines may be eligible to join, as long as they do not have other serious health problems like uncontrolled high blood pressure, diabetes, heart, liver, or kidney disease, other autoimmune conditions, or cancer. Pregnant women and those with other types of rheumatic diseases cannot participate. If you join, you can expect blood tests to measure TPI and ultrasound exams to check joint health. This study is not yet recruiting participants but aims to help doctors better understand RA and possibly improve ways to monitor the disease in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • - Adult patients with RA who fulfill 2010 ACR/EULAR classification criteria
• Exclusion Criteria:
• • 1. Individuals with uncontrolled chronic diseases such as hypertension , diabetes, heart disease, liver or kidney disease, other autoimmune disorders and tumors.
• • 2. Pregnant women.
• • 3. Rheumatologic diseases other than RA